GlassScriptPhysician profile
Donna Goodwin
NPI 1295255610
$4,105.36
in general payments reported to CMS, 2019-2025
29 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $404 · 2022: $485 · 2023: $612 · 2024: $1,140 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,215.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $896.57 | 2022-2025 | |
| Novo Nordisk INC | $554.34 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $427.92 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $309.50 | 2022-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $303.32 | 2021-2023 | Ajovy |
| Corcept Therapeutics | $220.33 | 2023-2024 | Korlym |
| Lilly USA, LLC | $206.56 | 2022-2025 | Zepbound, Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals LP | $203.41 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Xeris Pharmaceuticals, INC. | $185.00 | 2024-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Exact Sciences Corporation | $107.37 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $102.28 | 2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $98.30 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $74.03 | 2023-2025 | Veozah |
| Antares Pharma, INC. | $53.42 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Takeda Pharmaceuticals U.S.A., INC. | $48.16 | 2022-2023 | Vyvanse |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $38.76 | 2023 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $37.41 | 2024-2025 | Daybue |
| Ibsa Pharma INC. | $31.50 | 2022 | |
| Merck Sharp & Dohme LLC | $28.67 | 2022-2024 | Gardasil, Gardasil 9, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.58 | 2022 | |
| Lundbeck LLC | $21.85 | 2024 | Vyepti |
| Amarin Pharma, INC. | $21.02 | 2022 | |
| Organon LLC | $19.53 | 2025 | Nexplanon |
| Optinose US, INC. | $18.15 | 2024 | |
| Dynavax Technologies Corporation | $17.75 | 2025 | Heplisav-B |
| Amneal Pharmaceuticals LLC | $15.85 | 2025 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.70 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.63 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $13.45 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Goodwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.